RDIF and Panacea Biotec agree to produce 100 million doses of Sputnik V vaccine in India per year
Posted On: 2021-04-05 09:45:51 (Time Zone: Arizona, USA)
The Russian Direct Investment Fund (RDIF, Russia s sovereign wealth fund), and Panacea Biotec, one of the leading vaccine and pharmaceutical producers in India, announce cooperation to produce 100 million doses per year of Sputnik V, the world s first registered vaccine against coronavirus. Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF.
To date Sputnik V has been registered in 59 countries globally with total population of over 1.5 billion people. Efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet, one of the world s oldest and most respected medical journals.